Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: JNJ-7706621
  • Price: $550.0/100mg $1000.0/250mg $1900.0/1g $220.0/10ml
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

443797-96-4

443797-96-4 structure
443797-96-4 structure
  • Name: JNJ-7706621
  • Chemical Name: 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
  • CAS Number: 443797-96-4
  • Molecular Formula: C15H12F2N6O3S
  • Molecular Weight: 394.356
  • Catalog: Biochemical Inhibitor Cell Cycle CDK inhibitor
  • Create Date: 2018-12-11 21:31:46
  • Modify Date: 2024-01-09 11:09:31
  • JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.

Name 4-[[5-amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide
Synonyms 4-{[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino}benzenesulfonamide
Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
3ama
JNJ-7706621
Description JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.
Related Catalog
Target

CDK2/cyclinE:3 nM (IC50)

cdk2/cyclin A:4 nM (IC50)

Cdk1/cyclin B:9 nM (IC50)

CDK3/Cyclin E:58 nM (IC50)

CDK6/cyclinD1:175 nM (IC50)

Cdk4/cyclin D1:253 nM (IC50)

Aurora A:11 nM (IC50)

Aurora B:15 nM (IC50)

VEGF-R1:6400 nM (IC50)

VEGF-R2:154 nM (IC50)

VEGF-R3:735 nM (IC50)

FGF-R1:575 nM (IC50)

FGF-R2:226 nM (IC50)

GSK3β:254 nM (IC50)

In Vitro JNJ-7706621 shows antiproliferative activity against various human tumor cells with IC50s of 284, 254, and 447 nM for HeLa, HCT116, and A375, respectively[1]. JNJ-7706621 inhibits other centrosomal proteins such as TOG, Nek2, and TACC3 in early mitotic phase, but does not prevent localization of Aurora A to the spindle poles. Treatment of nocodazole-synchronized cells with JNJ-7706621 can override mitotic arrest by preventing spindle checkpoint signaling, resulting in failure of chromosome alignment and segregation[2]. JNJ-7706621 suspensions inhibits cell viability of HeLa cells with IC50s of 2.1 and 0.9 μg/mL at 24 and 48 h. The IC50 of the JNJ-7706621-loaded nanoparticles are 35 and 2.7 μg/mL and the IC50 of the JNJ-7706621-loaded micelles are 6.3 and 1.6 μg/mL[3]. JNJ-7706621 shows inhibition of Aurora-A and Aurora-B but has no activity at the highest concentration tested on the Plk1 or Wee1 serine/threonine kinases. JNJ-7706621 also shows potent growth inhibition in vitro on all human cancer cell types with IC50 values ranging from 112 to 514 nM[4].
In Vivo JNJ-7706621 (100 mg/kg, i.p.) exhibits 95% tumor growth inhibition in A375 (human melanoma) tumor xenograft model[1]. JNJ-7706621-loaded micelles inhibit tumor growth, and delay the tumor growth more efficiently than the control JNJ-7706621 suspension[3]. JNJ-7706621 (100 and 125 mg/kg) is efficacious in a human tumor xenograft model under intermittent dosing regimens[4].
Kinase Assay To identify compounds that inhibit CDK1 kinase activity, a screening method is developed using the CDK1/cyclin B complex to phosphorylate a biotinylated peptide substrate containing the consensus phosphorylation site for histone H1, which is phosphorylatedin vivo by CDK1. Inhibition of CDK1 activity is measured by observing a reduced amount of 33P-g-ATP incorporation into the immobilized substrate in streptavidin-coated 96-well scintillating microplates. CDK1 enzyme is diluted in 50 mM Tris-HCl (pH 8), 10 mM MgCl2, 0.1 mM Na3VO4, 1 mM DTT, 1% DMSO, 0.25 AM peptide, 0.1 ACi per well 33P-g-ATP (2,000-3,000 Ci/mmol), and 5 AM ATP in the presence or absence of various concentrations of test compound and incubated at 30°C for 1 hour. The reaction is terminated by washing with PBS containing 100 mM EDTA and plates are counted in a scintillation counter. Linear regression analysis of the percent inhibition by test compound is used to determine IC50 values. The Aurora kinase assays are done with 10 AM ATP and a peptide containing a dual repeat of the kemptide phosphorylation motif.
Cell Assay HeLa cells are seeded in 96-well plates at the density of 2500 viable cells per well. The cells are then incubated with a suspension of JNJ-7706621, JNJ-7706621-loaded micelles and nanoparticles (JNJ-7706621 concentrations of 0.011, 0.022, 0.11, 0.22, 1.1, 2.2, 11 and 22 μg/mL; dilutions are made in the medium) and drug-free polymeric micelles (polymers concentrations 0.3 mg/mL) and nanoparticles (polymers concentration 5 mg/mL) for 4, 24 and 48 h. The cytotoxicity is assessed using the MTT test. Absorbance is measured at 570 nm using a microplate reader. Untreated cells are taken as control with 100% viability and Triton X-100 1% is used as positive control of cytotoxicity. The results are expressed as mean values ± standard deviations of five measurements.
Animal Admin Briefly, animals are implanted s.c. with 1 mm3 A375 tumor fragments in the hindflank. After tumors reach 62 to 126 mg, groups are pair matched. Animals are given JNJ-7706621 or vehicle control starting on day 1. The tumor growth delay method is followed where each animal is euthanized when its neoplasm reached a predetermined size of 2.0 g. All statistical analyses are conducted using unpaired t tests at a P level of 0.05 (two tailed).
References

[1]. Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. Epub 2006 May 6.

[2]. Matsuhashi A, et al. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.

[3]. Danhier F, et al. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. Int J Pharm. 2010 Jun 15;392(1-2):20-8.

[4]. Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005 Oct 1;65(19):9038-46.

Density 1.7±0.1 g/cm3
Boiling Point 676.6±65.0 °C at 760 mmHg
Melting Point 149-155ºC
Molecular Formula C15H12F2N6O3S
Molecular Weight 394.356
Flash Point 363.0±34.3 °C
Exact Mass 394.065979
PSA 154.37000
LogP 0.18
Vapour Pressure 0.0±2.1 mmHg at 25°C
Index of Refraction 1.724
Storage condition -20℃
Water Solubility Soluble in DMSO at 15mg/ml
HS Code 2935009090

~%

443797-96-4 structure

443797-96-4

Literature: JANSSEN PHARMACEUTICA, N.V. Patent: WO2005/77922 A2, 2005 ; Location in patent: Page/Page column 46-47 ; WO 2005/077922 A2

~%

443797-96-4 structure

443797-96-4

Literature: JANSSEN PHARMACEUTICA, N.V. Patent: WO2005/77922 A2, 2005 ; Location in patent: Page/Page column 54-55 ; WO 2005/077922 A2

~%

443797-96-4 structure

443797-96-4

Literature: Lin, Ronghui; Connolly, Peter J.; Huang, Shenlin; Wetter, Steven K.; Lu, Yanhua; Murray, William V.; Emanuel, Stuart L.; Gruninger, Robert H.; Fuentes-Pesquera, Angel R.; Rugg, Catherine A.; Middleton, Steven A.; Jolliffe, Linda K. Journal of Medicinal Chemistry, 2005 , vol. 48, # 13 p. 4208 - 4211

~%

443797-96-4 structure

443797-96-4

Literature: Lin, Ronghui; Connolly, Peter J.; Huang, Shenlin; Wetter, Steven K.; Lu, Yanhua; Murray, William V.; Emanuel, Stuart L.; Gruninger, Robert H.; Fuentes-Pesquera, Angel R.; Rugg, Catherine A.; Middleton, Steven A.; Jolliffe, Linda K. Journal of Medicinal Chemistry, 2005 , vol. 48, # 13 p. 4208 - 4211

~%

443797-96-4 structure

443797-96-4

Literature: Lin, Ronghui; Connolly, Peter J.; Huang, Shenlin; Wetter, Steven K.; Lu, Yanhua; Murray, William V.; Emanuel, Stuart L.; Gruninger, Robert H.; Fuentes-Pesquera, Angel R.; Rugg, Catherine A.; Middleton, Steven A.; Jolliffe, Linda K. Journal of Medicinal Chemistry, 2005 , vol. 48, # 13 p. 4208 - 4211

~%

443797-96-4 structure

443797-96-4

Literature: Lin, Ronghui; Connolly, Peter J.; Huang, Shenlin; Wetter, Steven K.; Lu, Yanhua; Murray, William V.; Emanuel, Stuart L.; Gruninger, Robert H.; Fuentes-Pesquera, Angel R.; Rugg, Catherine A.; Middleton, Steven A.; Jolliffe, Linda K. Journal of Medicinal Chemistry, 2005 , vol. 48, # 13 p. 4208 - 4211

~%

443797-96-4 structure

443797-96-4

Literature: Lin, Ronghui; Connolly, Peter J.; Huang, Shenlin; Wetter, Steven K.; Lu, Yanhua; Murray, William V.; Emanuel, Stuart L.; Gruninger, Robert H.; Fuentes-Pesquera, Angel R.; Rugg, Catherine A.; Middleton, Steven A.; Jolliffe, Linda K. Journal of Medicinal Chemistry, 2005 , vol. 48, # 13 p. 4208 - 4211
HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%